Multiple Myeloma

Interim analysis results of the phase 3 MAIA trial demonstrated that frontline daratumumab plus lenalidomide/dexamethasone provided OS benefit compared with lenalidomide/dexamethasone in patients with NDMM ineligible for stem-cell transplantation. Read More ›

Results of the CARDAMON trial indicate that, although carfilzomib maintenance was feasible and yielded higher MRD negativity rates at 6 months with ASCT than with consolidation, it was associated with a higher incidence of grade ≥3 adverse events and discontinuations after ASCT. Read More ›

Results of a multicohort, phase 1/2 study indicated that the novel cereblon E3 ligase modulator iberdomide plus dexamethasone and daratumumab, bortezomib, or carfilzomib was associated with a tolerable safety profile and promising antitumor activity in patients with heavily pretreated RRMM. Read More ›

Preliminary data suggest that patients with both MM and WM show impaired serologic responses following COVID-19 vaccines, with more severe impairment of COVID-19 S-protein antibody responses observed in the Waldenström macroglobulinemia cohort, and mRNA-1273 eliciting higher responses than other vaccines. Read More ›

Updated results of the ICARIA-MM study demonstrated that addition of isatuximab to pomalidomide/low-dose dexamethasone led to significant improvements in efficacy outcomes compared with pomalidomide/low-dose dexamethasone alone in patients with RRMM. Read More ›

Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM. Read More ›

Updated results of the KarMMa trial showed that ide-cel CAR T-cell therapy resulted in durable and deep responses in heavily pretreated, triple-class–exposed patients with RRMM, supporting an overall favorable clinical benefit–risk profile. Read More ›

A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk. Read More ›

Final analysis results of the LYRA study demonstrated that daratumumab in combination with CyBorD induction therapy and as maintenance yielded durable and deep responses in patients with newly diagnosed or recurrent MM irrespective of ASCT status, with no new safety signals. Read More ›

A simulation modeling that incorporated clinically representative sequences for patients with transplant-ineligible NDMM and included attrition rates supports using the D-Rd regimen in the first-line setting instead of reserving it for later lines of therapy. Read More ›